Targeting antitumor CD4 helper T cells with universal tumor-reactive helper peptides derived from telomerase for cancer vaccine

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 5, 2013, Pages 1073-1077

  Adotévi, Olivier ^a,b,c,d   Dosset, Magalie ^a,b,c   Galaine, Jeanne ^a,b,c   Beziaud, Laurent ^a,b,c   Godet, Yann ^a,b,c   Borg, Christophe ^a,b,c,d  

^a INSERM   (France)

^b ETABLISSEMENT FRANÇAIS DU SANG   (France)

^c UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^d UNIVERSITY HOSPITAL OF BESANÇON   (France)

Author keywords

Cancer vaccine; CD4 T cell; Helper peptide; Telomerase

Indexed keywords

CANCER VACCINE; CD4 HELPER PEPTIDE; CYCLOPHOSPHAMIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PLATINUM COMPLEX; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG; UNIVERSAL CANCER PEPTIDE;

ANTIGEN PRESENTING CELL; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DEATH; DENDRITIC CELL; DRUG TARGETING; HUMAN; IMMUNOMODULATION; LUNG NON SMALL CELL CANCER; NONHUMAN; NOTE; T LYMPHOCYTE ACTIVATION;

CANCER VACCINE; CD4 T CELL; HELPER PEPTIDE; TELOMERASE;

CANCER VACCINES; HUMANS; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES, HELPER-INDUCER; TELOMERASE; VACCINES, SUBUNIT;

EID: 84878776860     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.23587     Document Type: Note

References (42)

1. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011; 29:235-71; PMID:21219185; http://dx.doi.org/10.1146/annurev-immunol-031210-101324.
2. Kennedy R, Celis E. Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol Rev 2008; 222:129-44; PMID:18363998; http://dx.doi.org/10. 1111/j.1600-065X.2008.00616.x.
3. Pardoll DM, Topalian SL. The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol 1998; 10:588-94; PMID:9794842; http://dx.doi.org/10. 1016/S0952-7915(98)80228-8.
4. Fayolle C, Deriaud E, Leclerc C. In vivo induction of cytotoxic T cell response by a free synthetic peptide requires CD4+ T cell help. J Immunol 1991; 147:4069-73; PMID:1684372.
5. Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 2008; 358:2698-703; PMID:18565862; http://dx.doi.org/10.1056/ NEJMoa0800251.
6. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998; 393:478-80; PMID:9624004; http://dx.doi.org/10.1038/30996.
7. Smith CM, Wilson NS, Waithman J, Villadangos JA, Carbone FR, Heath WR, et al. Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity. Nat Immunol 2004; 5:1143-8; PMID:15475958; http://dx.doi.org/10.1038/ ni1129.
8. Fehniger TA, Cooper MA, Nuovo GJ, Cella M, Facchetti F, Colonna M, et al. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood 2003; 101:3052-7; PMID:12480696; http://dx.doi.org/10. 1182/blood-2002-09-2876.
9. Qin Z, Blankenstein T. CD4+ T cell - mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity 2000; 12:677-86; PMID:10894167; http://dx.doi.org/10.1016/S1074-7613(00)80218-6.
10. Rakhra K, Bachireddy P, Zabuawala T, Zeiser R, Xu L, Kopelman A, et al. CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell 2010; 18:485-98; PMID:21035406; http://dx.doi.org/10.1016/j.ccr.2010.10.002.
11. Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12:298-306; PMID:22419253; http://dx.doi.org/10.1038/nrc3245.
12. Ladoire S, Arnould L, Mignot G, Apetoh L, Rébé C, Martin F, et al. T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival. Br J Cancer 2011; 105:366-71; PMID:21750556; http://dx.doi.org/10. 1038/bjc.2011.261.
13. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10:909-15; PMID:15340416; http://dx.doi.org/10. 1038/nm1100.
14. Kobayashi H, Celis E. Peptide epitope identification for tumor-reactive CD4 T cells. Curr Opin Immunol 2008; 20:221-7; PMID:18499419; http://dx.doi.org/10.1016/j.coi.2008.04.011.
15. Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 2005; 54:721-8; PMID:16010587; http://dx.doi.org/10.1007/s00262-004-0653-2.
16. Zhu J, Paul WE. CD4 T cells: fates, functions, and faults. Blood 2008; 112:1557-69; PMID:18725574; http://dx.doi.org/10.1182/blood-2008-05-078154.
17. De Monte L, Reni M, Tassi E, Clavenna D, Papa I, Recalde H, et al. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med 2011; 208:469-78; PMID:21339327; http://dx.doi.org/10.1084/jem.20101876.
18. Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 2011; 71:1263-71; PMID:21303976; http://dx.doi.org/10.1158/0008-5472.CAN-10- 2907.
19. Godet Y, Fabre E, Dosset M, Lamuraglia M, Levionnois E, Ravel P, et al. Analysis of spontaneous tumor-specific CD4 T-cell immunity in lung cancer using promiscuous HLA-DR telomerase-derived epitopes: potential synergistic effect with chemotherapy response. Clin Cancer Res 2012; 18:2943-53; PMID:22407833; http://dx.doi.org/10.1158/1078-0432.CCR-11-3185.
20. Martínez P, Blasco MA. Telomeric and extratelomeric roles for telomerase and the telomerebinding proteins. Nat Rev Cancer 2011; 11:161-76; PMID:21346783; http://dx.doi.org/10.1038/nrc3025.
21. Harley CB. Telomerase and cancer therapeutics. Nat Rev Cancer 2008; 8:167-79; PMID:18256617; http://dx.doi.org/10.1038/nrc2275.
22. Dosset M, Godet Y, Vauchy C, Beziaud L, Lone YC, Sedlik C, et al. Universal cancer peptide-based therapeutic vaccine breaks tolerance against telomerase and eradicates established tumor. Clin Cancer Res 2012; 18:6284-95; PMID:23032748; http://dx.doi.org/10.1158/1078-0432.CCR-12-0896.
23. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 1998; 393:474-8; PMID:9624003; http://dx.doi.org/10.1038/30989.
24. Adotévi O, Mollier K, Neuveut C, Dosset M, Ravel P, Fridman WH, et al. Targeting human telomerase reverse transcriptase with recombinant lentivector is highly effective to stimulate antitumor CD8 T-cell immunity in vivo. Blood 2010; 115:3025-32; PMID:20130242; http://dx.doi.org/10.1182/blood- 2009-11-253641.
25. Hernandez J, Garcia-Pons F, Lone YC, Firat H, Schmidt JD, Langlade-Demoyen P, et al. Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells. Proc Natl Acad Sci U S A 2002; 99:12275-80; PMID:12218171; http://dx.doi.org/10.1073/pnas.182418399.
26. Scardino A, Gross DA, Alves P, Schultze JL, Graff-Dubois S, Faure O, et al. HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J Immunol 2002; 168:5900-6; PMID:12023395.
27. del Guercio MF, Alexander J, Kubo RT, Arrhenius T, Maewal A, Appella E, et al. Potent immunogenic short linear peptide constructs composed of B cell epitopes and Pan DR T helper epitopes (PADRE) for antibody responses in vivo. Vaccine 1997; 15:441-8; PMID:9141216; http://dx.doi.org/10.1016/S0264-410X(97) 00186-2.
28. Helling F, Zhang S, Shang A, Adluri S, Calves M, Koganty R, et al. GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res 1995; 55:2783-8; PMID:7796403.
29. Scheibenbogen C, Schadendorf D, Bechrakis NE, Nagorsen D, Hofmann U, Servetopoulou F, et al. Effects of granulocyte-macrophage colony-stimulating factor and foreign helper protein as immunologic adjuvants on the T-cell response to vaccination with tyrosinase peptides. Int J Cancer 2003; 104:188-94; PMID:12569574; http://dx.doi.org/10.1002/ijc.10961.
30. Valmori D, Pessi A, Bianchi E, Corradin G. Use of human universally antigenic tetanus toxin T cell epitopes as carriers for human vaccination. J Immunol 1992; 149:717-21; PMID:1378079.
31. Slingluff CL Jr., Petroni GR, Chianese-Bullock KA, Smolkin ME, Ross MI, Haas NB, et al. Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine. J Clin Oncol 2011; 29:2924-32; PMID:21690475; http://dx.doi.org/10.1200/JCO.2010.33.8053.
32. Wong SB, Bos R, Sherman LA. Tumor-specific CD4+ T cells render the tumor environment permissive for infiltration by low-avidity CD8+ T cells. J Immunol 2008; 180:3122-31; PMID:18292535.
33. Marzo AL, Kinnear BF, Lake RA, Frelinger JJ, Collins EJ, Robinson BW, et al. Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity. J Immunol 2000; 165:6047-55; PMID:11086036.
34. Bos R, Sherman LA. CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res 2010; 70:8368-77; PMID:20940398; http://dx.doi.org/10.1158/0008-5472.CAN-10-1322.
35. Gross DA, Graff-Dubois S, Opolon P, Cornet S, Alves P, Bennaceur-Griscelli A, et al. High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. J Clin Invest 2004; 113:425-33; PMID:14755339.
36. Nakanishi Y, Lu B, Gerard C, Iwasaki A. CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help. Nature 2009; 462:510-3; PMID:19898495; http://dx.doi.org/10.1038/nature08511.
37. Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 2011; 8:151-60; PMID:21364688; http://dx.doi.org/10.1038/nrclinonc.2010.223.
38. Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012; 11:215-33; PMID:22301798; http://dx.doi.org/10.1038/nrd3626.
39. Godet Y, Dosset M, Borg C, Adotevi O. Is preexisting antitumor CD4 T cell response indispensable for the chemotherapy induced immune regression of cancer? Oncoimmunology 2012; 1:1617-9; PMID:23264913; http://dx.doi.org/10.4161/ onci.21513.
40. Ding ZC, Zhou G. Cytotoxic chemotherapy and CD4+ effector T cells: an emerging alliance for durable antitumor effects. Clin Dev Immunol 2012; 2012:890178; PMID:22400040; http://dx.doi.org/10.1155/2012/890178.
41. Terme M, Pernot S, Marcheteau E, Sandoval F, Benhamouda N, Colussi O, et al. VEGFA-VEGF Receptor pathway blockade inhibits tumor-induced regulatory T cell proliferation in colorectal cancer. Cancer Res 2013; 73:539-49; PMID:23108136; http://dx.doi.org/10.1158/0008-5472.CAN-12-2325.
42. Adotevi O, Pere H, Ravel P, Haicheur N, Badoual C, Merillon N, et al. A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients. J Immunother 2010; 33:991-8; PMID:20948437; http://dx.doi.org/10.1097/CJI. 0b013e3181f4c208.